![]() Biosceptre Wins SMART Award GrantBiosceptre Wins Funding from the UK Government-Backed, SMART Award to Develop Novel cancer Diagnostic and Therapeutic Targets
By: Biosceptre Biosceptre's diagnostic and therapeutic candidates are based on its proprietary nf-P2X7 platform. This platform utilises antibody- and peptide-based approaches to target nf-P2X7, a unique variant of the P2X7 receptor present on the surface of cancerous but not normal cells. Biosceptre has established freedom to operate and a strong global patent portfolio. Antibodies targeting nf-P2X7 have shown specificity, safety and efficacy in pre-clinical studies. A phase I trial has confirmed safety and provided a strong indication of efficacy against basal cell carcinoma. Hence, nf-P2X7 can be targeted safely and effectively. Gavin Currie, Biosceptre's CEO, said, "Biosceptre is delighted to receive funding from the UK's innovation agency to progress the development of our novel diagnostics and therapeutics targeting cancer. Successfully winning funding represents a major vote of confidence in our approaches to target cancer through nf-P2X7. This award recognises the need for effective new diagnostic and therapeutic approaches against cancer, and the potential of our technology to protect against a wide range of disease-causing strains." http://www.biosceptre.com End
|